Scott shares 50 diverse links covering topics from AI developments to policy changes, with commentary on current events, research findings, and societal trends.

Scott Alexander and 1DaySooner outline potential positive health policy initiatives that could emerge under three key Trump administration health appointees: Jim O'Neill, Marty Makary, and Jay Bhattacharya.

The post explores the Far Out Initiative's goal to eliminate suffering through biotechnology, inspired by a pain-free woman and David Pearce's philosophy.

Scott Alexander shares reader comments on his California ballot recommendations, updating some of his views and providing additional context on various races and propositions.

Scott responds to various comments on his article about supplement labeling, addressing concerns about the industry and providing additional context and analysis.

Scott Alexander reviews comments on his posts about aducanumab and the FDA, acknowledging some mistakes while defending his overall critique of FDA conservatism.

Scott Alexander examines the treatment for progeria and its potential implications for understanding and treating normal aging processes.

Scott Alexander summarizes reader comments about CBT-i apps, their effectiveness, pricing challenges, and FDA regulation.

Scott Alexander criticizes the emergence of expensive, prescription-only therapy apps, using Somryst (a CBT-i app) as an example, and warns about the normalization of this trend.

Scott Alexander investigates the optimal dosage of Lexapro, comparing it to other antidepressants and exploring the reasons behind its effectiveness at lower doses.

Scott Alexander explores the history and mechanism of DNP, a dangerous but effective weight-loss drug, and discusses recent developments in safer mitochondrial uncoupling agents.

Scott Alexander critiques the FDA approval of esketamine for depression, discussing issues with drug development, efficacy, cost, and administration requirements.

Scott Alexander offers various strategies for obtaining affordable mental health care and medication in the US, including discount programs, therapy alternatives, and supplement options.

Scott Alexander shares a diverse collection of interesting links covering topics from architecture to AI, with brief summaries and occasional humorous commentary.

Scott Alexander argues that the 33% rate of post-marketing safety events for FDA-approved drugs is not necessarily concerning and explains why post-marketing surveillance is a normal part of drug safety monitoring.

Scott argues against Vox's proposal for drug price controls, citing studies that such policies would significantly reduce pharmaceutical innovation and potentially cost millions of life-years long-term.

Scott Alexander argues that the EpiPen price hike is due to over-regulation and cronyism in the pharmaceutical industry, not lack of regulation as suggested by Vox.

The post examines three major issues with generic medications: barriers to market entry, problematic FDA initiatives, and inconsistent pricing across pharmacies.